This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

NICE guidance - Adalimumab for the treatment of psoriasis

Authoring team

Summary features of the guidance (1):

  • NICE state that:
    • adalimumab is recommended as a possible treatment for adults with plaque psoriasis only if:
      • their condition is severe and
      • their condition has not improved with other treatments such as ciclosporin, methotrexate and PUVA (psoralen and long-wave ultraviolet radiation), or they have had side effects with these in the past or there is a medical reason why they should not be given these treatments.
    • adalimumab treatment should be continued beyond 16 weeks only if the psoriasis has clearly improved within this time.
    • severity of a person's psoriasis before and during treatment should be assessed by considering the redness, thickness and scaliness of the plaques, the area of the body involved, and how the condition affects the person's quality of life.

For further details then consult the full guideline (1).

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.